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Foreword 
 
The evaluation of research and doctoral training is being carried out in the years 2010–2012 and will end in 
2012. The steering group appointed by the Rector in January 2010 set the conditions for participating in 
the evaluation and prepared the Terms of Reference to present the evaluation procedure and criteria. The 
publications and other scientific activities included in the evaluation covered the years 2005–2010. 
The participating unit in the evaluation was defined as a Researcher Community (RC). To obtain a 
critical mass with university-level impact, the number of members was set to range from 20 to 120. The 
RCs were required to contain researchers in all stages of their research career, from doctoral students to 
principal investigators (PIs). All in all, 136 Researcher Communities participated in this voluntary 
evaluation, 5857 persons in total, of whom 1131 were principal investigators. PIs were allowed to 
participate in two communities in certain cases, and 72 of them used this opportunity and participated in 
two RCs. 
This evaluation enabled researchers to define RCs from the “bottom up” and across disciplines. The aim 
of the evaluation was not to assess individual performance but a community with shared aims and 
researcher-training activities. The RCs were able to choose among five different categories that 
characterised the status and main aims of their research. The steering group considered the process of 
applying to participate in the evaluation to be important, which lead to the establishment of these 
categories. In addition, providing a service for the RCs to enable them to benchmark their research at the 
global level was a main goal of the evaluation. 
The data for the evaluation consisted of the RCs’ answers to evaluation questions on supplied e-forms 
and a compilation extracted from the TUHAT – Research Information System (RIS) on 12 April 2011. The 
compilation covered scientific and other publications as well as certain areas of scientific activities. During 
the process, the RCs were asked to check the list of publications and other scientific activities and make 
corrections if needed. These TUHAT compilations are public and available on the evaluation project sites 
of each RC in the TUHAT-RIS. 
In addition to the e-form and TUHAT compilation, University of Leiden (CWTS) carried out bibliometric 
analyses from the articles included in the Web of Science (WoS). This was done on University and RC 
levels. In cases where the publication forums of the RC were clearly not represented by the WoS data, the 
Library of the University of Helsinki conducted a separate analysis of the publications. This was done for 
66 RCs representing the humanities and social sciences. 
The evaluation office also carried out an enquiry targeted to the supervisors and PhD candidates about 
the organisation of doctoral studies at the University of Helsinki. This and other documents describing the 
University and the Finnish higher education system were provided to the panellists. 
The panel feedback for each RC is unique and presented as an entity. The first collective evaluation 
reports available for the whole panel were prepared in July–August 2011. The reports were accessible to all 
panel members via the electronic evaluation platform in August. Scoring from 1 to 5 was used to 
complement written feedback in association with evaluation questions 1–4 (scientific focus and quality, 
doctoral training, societal impact, cooperation) and in addition to the category evaluating the fitness for 
participation in the evaluation. Panellists used the international level as a point of comparison in the 
evaluation. Scoring was not expected to go along with a preset deviation. 
Each of the draft reports were discussed and dealt with by the panel in meetings in Helsinki (from 11 
September to 13 September or from 18 September to 20 September 2011). In these meetings the panels 
also examined the deviations among the scores and finalised the draft reports together. 
The current RC-specific report deals shortly with the background of the evaluation and the terms of 
participation. The main evaluation feedback is provided in the evaluation report, organised according to 
the evaluation questions. The original material provided by the RCs for the panellists has been attached to 
these documents. 
 
 
 
 
 
 
 
 
 
On behalf of the evaluation steering group and office, I sincerely wish to thank you warmly for your 
participation in this evaluation. The effort you made in submitting the data to TUHAT-RIS is gratefully 
acknowledged by the University. We wish that you find this panel feedback useful in many ways. The 
bibliometric profiles may open a new view on your publication forums and provide a perspective for 
discussion on your choice of forums. We especially hope that this evaluation report will help you in setting 
the future goals of your research. 
 
Johanna Björkroth 
Vice-Rector 
Chair of the Steering Group of the Evaluation 
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BA Liisa Jäppinen, Assisting Officer, served in TUHAT-RIS updating the 
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Acronyms and abbreviations applied in the report 
 
External competitive funding 
AF – Academy of Finland 
TEKES - Finnish Funding Agency for Technology and Innovation  
EU - European Union 
ERC - European Research Council 
International and national foundations 
FP7/6 etc. /Framework Programmes/Funding of European Commission 
 
Evaluation marks 
Outstanding (5) 
Excellent  (4) 
Very Good  (3) 
Good  (2) 
Sufficient  (1) 
 
Abbreviations of Bibliometric Indicators 
P - Number of publications 
TCS – Total number of citations 
MCS - Number of citations per publication, excluding self-citations 
PNC - Percentage of uncited publications 
MNCS - Field-normalized number of citations per publication 
MNJS - Field-normalized average journal impact 
THCP10 - Field-normalized proportion highly cited publications (top 10%) 
INT_COV - Internal coverage, the average amount of references covered by the WoS 
WoS – Thomson Reuters Web of Science Databases 
 
Participation category 
Category 1. The research of the participating community represents the international cutting edge in its 
field. 
Category 2. The research of the participating community is of high quality, but the community in its 
present composition has yet to achieve strong international recognition or a clear break-through. 
Category 3. The research of the participating community is distinct from mainstream research, and the 
special features of the research tradition in the field must be considered in the evaluation. 
Category 4. The research of the participating community represents an innovative opening. 
Category 5. The research of the participating community has a highly significant societal impact. 
 
Research focus areas of the University of Helsinki 
Focus area 1: The basic structure, materials and natural resources of the physical world 
Focus area 2: The basic structure of life 
Focus area 3: The changing environment – clean water 
Focus area 4: The thinking and learning human being 
Focus area 5: Welfare and safety 
Focus area 6: Clinical research 
Focus area 7: Precise reasoning 
Focus area 8: Language and culture 
Focus area 9: Social justice 
Focus area 10: Globalisation and social change 
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1 Introduction to the Evaluation 
1.1 RC-specific evaluation reports 
The participants in the evaluation of research and doctoral training were Researcher Communities 
(hereafter referred to as the RC). The RC refers to the group of researchers who registered together in the 
evaluation of their research and doctoral training. Preconditions in forming RCs were stated in the 
Guidelines for the Participating Researcher Communities. The RCs defined themselves whether their 
compositions should be considered well-established or new. 
It is essential to emphasise that the evaluation combines both meta-evaluation1 and traditional 
research assessment exercise and its focus is both on the research outcomes and procedures associated 
with research and doctoral training. The approach to the evaluation is enhancement-led where self-
evaluation constituted the main information. The answers to the evaluation questions formed together 
with the information of publications and other scientific activities an entity that was to be reviewed as a 
whole. 
The present evaluation recognizes and justifies the diversity of research practices and publication 
traditions. Traditional Research Assessment Exercises do not necessarily value high quality research with 
low volumes or research distinct from mainstream research. It is challenging to expose the diversity of 
research to fair comparison. To understand the essence of different research practices and to do justice to 
their diversity was one of the main challenges of the present evaluation method. Understanding the 
divergent starting points of the RCs demanded sensitivity from the evaluators. 
1.2 Aims and objectives in the evaluation 
The aims of the evaluation are as follows: 
 to improve the level of research and doctoral training at the University of Helsinki and to raise 
their international profile in accordance with the University’s strategic policies. The improvement 
of doctoral training should be compared to the University’s policy.2 
 to enhance the research conducted at the University by taking into account the diversity, 
originality, multidisciplinary nature, success and field-specificity, 
 to recognize the conditions and prerequisites under which excellent, original and high-impact 
research is carried out, 
 to offer the academic community the opportunity to receive topical and versatile international 
peer feedback, 
 to better recognize the University’s research potential. 
 to exploit the University’s TUHAT research information system to enable transparency of 
publishing activities and in the production of reliable, comparable data. 
1.3 Evaluation method 
The evaluation can be considered as an enhancement-led evaluation. Instead of ranking, the main aim is to 
provide useful information for the enhancement of research and doctoral training of the participating RCs. 
The comparison should take into account each field of science and acknowledge their special character. 
                                                                
1 The panellists did not read research reports or abstracts but instead, they evaluated answers to the evaluation 
questions, tables and compilations of publications, other scientific activities, bibliometrics or comparable analyses. 
2
 Policies on doctoral degrees and other postgraduate degrees at the University of Helsinki.  
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The comparison produced information about the present status and factors that have lead to success. Also 
challenges in the operations and outcomes were recognized. 
The evaluation approach has been designed to recognize better the significance and specific nature of 
researcher communities and research areas in the multidisciplinary top-level university. Furthermore, one 
of the aims of the evaluation is to bring to light those evaluation aspects that differ from the prevalent 
ones. Thus the views of various fields of research can be described and research arising from various 
starting points understood better. The doctoral training is integrated into the evaluation as a natural 
component related to research. Operational processes of doctoral training are being examined in the 
evaluation. 
 
Five stages of the evaluation method were: 
1. Registration – Stage 1 
2. Self-evaluation – Stage 2 
3. TUHAT3 compilations on publications and other scientific activities4 
4. External evaluation 
5. Public reporting 
1.4 Implementation of the external evaluation 
Five Evaluation Panels 
Five evaluation panels consisted of independent, renowned and highly respected experts. The main 
domains of the panels are: 
1. biological, agricultural and veterinary sciences 
2. medicine, biomedicine and health sciences 
3. natural sciences 
4. humanities 
5. social sciences 
The University invited 10 renowned scientists to act as chairs or vice-chairs of the five panels based on 
the suggestions of faculties and independent institutes. Besides leading the work of the panel, an 
additional role of the chairs was to discuss with other panel chairs in order to adopt a broadly similar 
approach. The panel chairs and vice-chairs had a pre-meeting on 27 May 2011 in Amsterdam. 
The panel compositions were nominated by the Rector of the University 27 April 2011. The participating 
RCs suggested the panel members. The total number of panel members was 50. The reason for a smaller 
number of panellists as compared to the previous evaluations was the character of the evaluation as a 
meta-evaluation. The panellists did not read research reports or abstracts but instead, they evaluated 
answers to the evaluation questions, tables and compilations of publications, other scientific activities, 
bibliometrics and comparable analyses. 
 
The panel meetings were held in Helsinki: 
 On 11–13 September 2011: (1) biological, agricultural and veterinary sciences, (2) medicine, 
biomedicine and health sciences and (3) natural sciences.  
 On 18–20 September 2011: (4) humanities and (5) social sciences. 
  
                                                                
3 TUHAT (acronym) of Research Information System (RIS) of the University of Helsinki 
4 Supervision of thesis, prizes and awards, editorial work and peer reviews, participation in committees, boards and 
networks and public appearances. 
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1.5 Evaluation material 
The main material in the evaluation was the RCs’ self-evaluations that were qualitative in character and 
allowed the RCs to choose what was important to mention or emphasise and what was left unmentioned. 
The present evaluation is exceptional at least in the Finnish context because it is based on both the 
evaluation documentation (self-evaluation questions, publications and other scientific activities) and the 
bibliometric reports. All documents were delivered to the panellists for examination. 
Traditional bibliometrics can be reasonably done mainly in medicine, biosciences and natural sciences 
when using the Web of Science database, for example. Bibliometrics, provided by CWTS/The Centre for 
Science and Technology Studies, University of Leiden, cover only the publications that include WoS 
identification in the TUHAT-RIS. 
Traditional bibliometrics are seldom relevant in humanities and social sciences because the 
international comparable databases do not store every type of high quality research publications, such as 
books and monographs and scientific journals in other languages than English. The Helsinki University 
Library has done analysis to the RCs, if their publications were not well represented in the Web of Science 
databases (RCs should have at least 50 publications and internal coverage of publications more than 40%) 
– it meant 58 RCs. The bibliometric material for the evaluation panels was available in June 2011. The RC-
specific bibliometric reports are attached at the end of each report. 
The panels were provided with the evaluation material and all other necessary background information, 
such as the basic information about the University of Helsinki and the Finnish higher education system. 
 
Evaluation material 
1. Registration documents of the RCs for the background information 
2. Self evaluation material – answers to the evaluation questions 
3. Publications and other scientific activities based on the TUHAT RIS: 
3.1. statistics of publications 
3.2. list of publications 
3.3. statistics of other scientific activities 
3.4. list of other scientific activities 
4. Bibliometrics and comparable analyses: 
4.1. Analyses of publications based on the verification of TUHAT-RIS publications with the Web 
of Science publications (CWTS/University of Leiden) 
4.2. Publication statistics analysed by the Helsinki University Library - mainly for humanities and 
social sciences 
5. University level survey on doctoral training (August 2011) 
6. University level analysis on publications 2005–2010 (August 2011) provided by CWTS/University 
of Leiden 
 
Background material 
 
University of Helsinki 
- Basic information about the University of the Helsinki 
- The structure of doctoral training at the University of Helsinki 
- Previous evaluations of research at the University of Helsinki – links to the reports: 1998 and 2005 
 
The Finnish Universities/Research Institutes 
- Finnish University system 
- Evaluation of the Finnish National Innovation System 
- The State and Quality of Scientific Research in Finland. Publication of the Academy of Finland 
9/09. 
 
The evaluation panels were provided also with other relevant material on request before the meetings in 
Helsinki. 
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1.6 Evaluation questions and material 
The participating RCs answered the following evaluation questions which are presented according to the 
evaluation form. In addition, TUHAT RIS was used to provide the additional material as explained. For 
giving the feedback to the RCs, the panellists received the evaluation feedback form constructed in line 
with the evaluation questions: 
 
1. Focus and quality of the RC’s research 
 Description of 
- the RC’s research focus. 
- the quality of the RC’s research (incl. key research questions and results) 
- the scientific significance of the RC’s research in the research field(s) 
 Identification of the ways to strengthen the focus and improve the quality of the RC’s research 
The additional material: TUHAT compilation of the RC’s publications, analysis of the RC’s publications data 
(provided by University of Leiden and the Helsinki University Library) 
A written feedback from the aspects of: scientific quality, scientific significance, societal impact, 
innovativeness 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
2. Practises and quality of doctoral training 
 Organising of the doctoral training in the RC. Description of the RC’s principles for: 
- recruitment and selection of doctoral candidates 
- supervision of doctoral candidates 
- collaboration with faculties, departments/institutes, and potential graduate schools/doctoral 
programmes 
- good practises and quality assurance in doctoral training 
- assuring of good career perspectives for the doctoral candidates/fresh doctorates 
 Identification of the RC’s strengths and challenges related to the practises and quality of doctoral 
training, and the actions planned for their development. 
The additional material: TUHAT compilation of the RC’s other scientific activities/supervision of doctoral 
dissertations 
A written feedback from the aspects of: processes and good practices related to leadership and 
management 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
3. The societal impact of research and doctoral training 
 Description on how the RC interacts with and contributes to the society (collaboration with 
public, private and/or 3rd sector). 
 Identification of the ways to strengthen the societal impact of the RC’s research and doctoral 
training. 
The additional material: TUHAT compilation of the RC’s other scientific activities. 
A written feedback from the aspects of: societal impact, national and international collaboration, 
innovativeness 
 
  Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
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4. International and national (incl. intersectoral) research collaboration and researcher mobility 
 Description of  
- the RC’s research collaborations and joint doctoral training activities 
- how the RC has promoted researcher mobility 
 Identification of the RC’s strengths and challenges related to research collaboration and 
researcher mobility, and the actions planned for their development. 
A written feedback from the aspects of: scientific quality, national and international collaboration 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
5. Operational conditions  
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties). 
 Identification of the RC’s strengths and challenges related to operational conditions, and the 
actions planned for their development. 
A written feedback from the aspects of: processes and good practices related to leadership and 
management 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
6. Leadership and management in the researcher community 
 Description of 
- the execution and processes of leadership in the RC 
- how the management-related responsibilities and roles are distributed in the RC 
- how the leadership- and management-related processes support 
- high quality research 
- collaboration between principal investigators and other researchers in the RC 
the RC’s research focus 
- strengthening of the RC’s know-how 
 Identification of the RC’s strengths and challenges related to leadership and management, and 
the actions planned for developing the processes 
 
7. External competitive funding of the RC 
 The RCs were asked to provide information of such external competitive funding, where: 
- the funding decisions have been made during 1.1.2005-31.12.2010, and 
- the administrator of the funding is/has been the University of Helsinki 
 On the e-form the RCs were asked to provide: 
1) The relevant funding source(s) from a given list (Academy of Finland/Research Council, TEKES/The 
Finnish Funding Agency for Technology and Innovation , EU, ERC, foundations, other national funding 
organisations, other international funding organisations), and 
2)The total sum of funding which the organisation in question had decided to allocate to the RCs 
members during 1.1.2005–31.12.2010. 
 
Competitive funding reported in the text is also to be considered when evaluating this point. 
A written feedback from the aspects of: scientific quality, scientific significance, societal impact, 
innovativeness, future significance 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
8. The RC’s strategic action plan for 2011–2013 
 RC’s description of their future perspectives in relation to research and doctoral training. 
A written feedback from the aspects of: scientific quality, scientific significance, societal Impact, processes 
and good practices related to leadership and management, national and international collaboration, 
innovativeness, future significance 
 Strengths 
 Areas of development 
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 Other remarks 
 Recommendations 
 
9. Evaluation of the category of the RC in the context of entity of the evaluation material (1-8) 
 
The RC’s fitness to the chosen participation category 
A written feedback evaluating the RC’s fitness to the chosen participation category  
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
10. Short description of how the RC members contributed the compilation of the stage 2 material 
Comments on the compilation of evaluation material 
 
11. How the UH’s focus areas are presented in the RC’s research? 
Comments if applicable 
 
12. RC-specific main recommendations based on the previous questions 1–11 
 
13. RC-specific conclusions 
1.7 Evaluation criteria 
The panellists were expected to give evaluative and analytical feedback to each evaluation question 
according to their aspects in order to describe and justify the quality of the submitted material. In 
addition, the evaluation feedback was asked to be pointed out the level of the performance according to 
the following classifications: 
 outstanding  (5) 
 excellent  (4) 
 very good  (3) 
 good   (2) 
 sufficient  (1) 
 
Evaluation according to the criteria was to be made with thorough consideration of the entire 
evaluation material of the RC in question. Finally, in questions 1-4 and 9, the panellists were expected to 
classify their written feedback into one of the provided levels (the levels included respective descriptions, 
‘criteria’). Some panels used decimals in marks. The descriptive level was interpreted according to the 
integers and not rounding up the decimals by the editors. 
 
Description of criteria levels 
Question 1 – FOCUS AND QUALITY OF THE RC’S RESEARCH 
 
Classification: Criteria (level of procedures and results) 
Outstanding quality of procedures and results (5) 
Outstandingly strong research, also from international perspective. Attracts great international 
interest with a wide impact, including publications in leading journals and/or monographs published 
by leading international publishing houses. The research has world leading qualities. The research 
focus, key research questions scientific significance, societal impact and innovativeness are of 
outstanding quality. 
In cases where the research is of a national character and, in the judgement of the evaluators, should 
remain so, the concepts of ”international attention” or ”international impact” etc. in the grading 
criteria above may be replaced by ”international comparability”. 
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Operations and procedures are of outstanding quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are in 
alignment with the documentation. The ambition to develop the community together is of 
outstanding quality. 
Excellent quality of procedures and results (4) 
Research of excellent quality. Typically published with great impact, also internationally. Without 
doubt, the research has a leading position in its field in Finland. 
Operations and procedures are of excellent quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are to 
large extent in alignment with the documentation. The ambition to develop the community together 
is of excellent quality. 
Very good quality of procedures and results (3) 
The research is of such very good quality that it attracts wide national and international attention. 
Operations and procedures are of very good quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are to 
large extent in alignment with the documentation. The ambition to develop the community together 
is of very good quality. 
Good quality of procedures and results (2) 
Good research attracting mainly national attention but possessing international potential, 
extraordinarily high relevance may motivate good research. 
Operations and procedures are of good quality, shared occasionally in the community. The 
improvement of research and other efforts are occasionally documented and operations and 
practices are to large extent in alignment with the documentation. The ambition to develop the 
community together is of good quality. 
Sufficient quality of procedures and results (1) 
In some cases the research is insufficient and reports do not gain wide circulation or do not have 
national or international attention. Research activities should be revised. 
Operations and procedures are of sufficient quality, shared occasionally in the community. The 
improvement of research and other efforts are occasionally documented and operations and 
practices are to some extent in alignment with the documentation. The ambition to develop the 
community together is of sufficient quality. 
 
Question 2 – DOCTORAL TRAINING 
Question 3 – SOCIETAL IMPACT 
Question 4 – COLLABORATION 
 
Classification: Criteria (level of procedures and results) 
Outstanding quality of procedures and results (5) 
Procedures are of outstanding quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are in alignment with the 
documentation. The ambition to develop the community together is of outstanding quality. The 
procedures and results are regularly evaluated and the feedback has an effect on the planning. 
Excellent quality of procedures and results (4) 
Procedures are of excellent quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of excellent quality. The 
procedures and outcomes are evaluated and the feedback has an effect on the planning. 
Very good quality of procedures and results (3) 
Procedures are of very good quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
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management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of very good quality. 
Good quality of procedures and results (2) 
Procedures are of good quality, shared occasionally in the community. The practices and quality of 
doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of good quality. 
Sufficient quality of procedures and results (1) 
Procedures are of sufficient quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are occasionally documented and operations and practices are to some extent in 
alignment with the documentation. The ambition to develop the community together is of sufficient 
quality. 
 
Question 9 – CATEGORY 
Participation category – fitness for the category chosen 
The choice and justification for the chosen category below should be reflected in the RC’s responses to the 
evaluation questions 1–8. 
1. The research of the participating community represents the international cutting edge in its field. 
2. The research of the participating community is of high quality, but the community in its present 
composition has yet to achieve strong international recognition or a clear break-through. 
3. The research of the participating community is distinct from mainstream research, and the special 
features of the research tradition in the field must be considered in the evaluation. The research is 
of high quality and has great significance and impact in its field. However, the generally used 
research evaluation methods do not necessarily shed sufficient light on the merits of the 
research.  
4. The research of the participating community represents an innovative opening. A new opening can 
be an innovative combination of research fields, or it can be proven to have a special social, 
national or international demand or other significance. Even if the researcher community in its 
present composition has yet to obtain proof of international success, its members can produce 
convincing evidence of the high level of their previous research. 
5. The research of the participating community has a highly significant societal impact. The 
participating researcher community is able to justify the high social significance of its research. 
The research may relate to national legislation, media visibility or participation in social debate, 
or other activities promoting social development and human welfare. In addition to having 
societal impact, the research must be of a high standard. 
 
An example of outstanding fitness for category choice (5) 5 
The RC’s representation and argumentation for the chosen category were convincing. The RC recognized 
its real capacity and apparent outcomes in a wider context to the research communities. The specific 
character of the RC was well-recognized and well stated in the responses. The RC fitted optimally for the 
category. 
 
 Outstanding  (5) 
 Excellent  (4) 
 Very good  (3) 
 Good   (2) 
 Sufficient  (1) 
The above-mentioned definition of outstanding was only an example in order to assist the panellists in 
the positioning of the classification. There was no exact definition for the category fitness. 
                                                                
5 The panels discussed the category fitness and made the final conclusions of the interpretation of it. 
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1.8 Timetable of the evaluation 
The main timetable of the evaluation: 
1. Registration   November 2010 
2. Submission of self-evaluation materials  January–February 2011 
3. External peer review    May–September 2011 
4. Published reports    March–April 2012 
- University level public report 
- RC specific reports 
 
The entire evaluation was implemented during the university’s strategy period 2010–2012. The preliminary 
results were available for the planning of the following strategy period in late autumn 2011. The evaluation 
reports will be published in March/April 2012. More detailed time schedule is published in the University 
report. 
1.9 Evaluation feedback – consensus of the entire panel 
The panellists evaluated all the RC-specific material before the meetings in Helsinki and mailed the 
draft reports to the evaluation office. The latest interim versions were on-line available to all the panellists 
on the Wiki-sites. In September 2011, in Helsinki the panels discussed the material, revised the first draft 
reports and decided the final numeric evaluation. After the meetings in Helsinki, the panels continued 
working and finalised the reports before the end of November 2011. The final RC-specific reports are the 
consensus of the entire panel. 
The evaluation reports were written by the panels independently. During the editing process, the 
evaluation office requested some clarifications from the panels when necessary. The tone and style in the 
reports were not harmonized in the editing process. All the reports follow the original texts written by the 
panels as far as it was possible. 
The original evaluation material of the RCs, provided for the panellists is attached at the end of the 
report. It is essential to notice that the exported lists of publications and other scientific activities depend 
how the data was stored in the TUHAT-RIS by the RCs. 
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2 Evaluation feedback 
2.1 Focus and quality of the RC’s research 
 Description of 
 the RC’s research focus 
 the quality of the RC’s research (incl. key research questions and results) 
 the scientific significance of the RC’s research in the research field(s) 
 Identification of the ways to strengthen the focus and improve the quality of the RC’s research 
ASPECTS: Scientific quality, scientific significance, societal impact, innovativeness 
 
Strengths: High quality scientific research, combination of basic and clinical research. Application into 
common and therefore important skin and allergy diseases. Development of treatments for common 
diseases, and therefore high societal impact and scientific significance. Societal impact is also 
accomplished by visible presence at high level international meetings, in media etc. The research is 
innovative. 
Good networking and scientific cooperation with various research groups outside dermatology and 
allergy. Intensive international cooperation. 
Areas of development correspond to those which can be expected in the future to be important in the 
fields of dermatology and allergy. 
Good level of publications. Of positive note is the involvement of many young talented scientists and 
the promotion of their carriers. 
Recommendations: Recommendation that the group continues their successful work as in the past, 
and the support by the university to the clinical and research efforts is increased. 
Numeric evaluation: 4 (Excellent) 
2.2 Practises and quality of doctoral training 
 Organising of the doctoral training in the RC. Description of the RC’s principles for: 
 recruitment and selection of doctoral candidates 
 supervision of doctoral candidates 
 collaboration with faculties, departments/institutes, and potential graduate schools/doctoral 
programmes 
 good practises and quality assurance in doctoral training 
 assuring of good career perspectives for the doctoral candidates/fresh doctorates 
 Identification of the RC’s strengths and challenges related to the practises and quality of doctoral 
training, and the actions planned for their development. 
 Additional material: TUHAT compilation of the RC’s other scientific activities/supervision of doctoral 
dissertations 
ASPECTS: Processes and good practices related to leadership and management 
 
Very good selection and recruitment of doctoral candidates. Stimulation of physician-scientist or MD/PhD 
careers. 
Very good supervision of doctoral candidates, excellent collaboration with other faculties, institutes 
and programs. 
Good practice and quality assessment in doctoral training and assurance of career perspectives by the 
doctoral candidates/fresh doctorates. 
Numeric evaluation: 4 (Excellent) 
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2.3 The societal impact of research and doctoral training 
 Description on how the RC interacts with and contributes to the society (collaboration with public, 
private and/or 3rd sector). 
 Identification of the ways to strengthen the societal impact of the RC’s research and doctoral training. 
 Additional material: TUHAT compilation of the RC’s other scientific activities. 
ASPECTS: Societal impact, national and international collaboration, innovativeness 
 
The RC interacts very well with the society. It is present at many large international meetings, and its work 
is highly visible and well known. An intensive international research network contributes to the visibility of 
research. 
The societal impact is very high due to high quality research in very important skin and allergic 
diseases which are common in the general population. Major contributions have been made in these fields 
by the RC. 
Recommendations: Please consider a higher presence in mass media which are quite interested in the 
fields of skin cancer and allergies. 
Numeric evaluation: 4 (Excellent) 
2.4 International and national (incl. intersectoral) research 
collaboration and researcher mobility 
 Description of  
 the RC’s research collaborations and joint doctoral training activities 
 how the RC has promoted researcher mobility 
 Identification of the RC’s strengths and challenges related to research collaboration and researcher 
mobility, and the actions planned for their development. 
ASPECTS: Scientific quality, national and international collaboration 
 
Very strong research collaborations and joint activities, among others within EU programs. Very good 
researcher mobility. The panel’s recommendation is to continue this successful effort at the same level. 
EU funding (6 m €) for ten partners for the future research in MAARS (Microbes in Allergy and 
Autoimmunity Related to Skin) is excellent and secures the RC’s position in international collaboration. 
Numeric evaluation: 5 (Outstanding) 
2.5 Operational conditions 
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties). 
 Identification of the RC’s strengths and challenges related to operational conditions, and the actions 
planned for their development. 
ASPECTS: Processes and good practices related to leadership and management 
 
From the description of work provided by Professor Ranki, the impression arises, that university support 
could be increased. The work and output provided by the RC are important for the university and the 
general public, and the research environment should be improved. The difficulties faced by 
clinicians/scientists are the same all over the world with a difficult splitting of time between clinical work, 
research and teaching as well as administrative duties. This can only be improved if the staff number is 
increased so that researchers have fewer duties in clinical and teaching terms. 
Recommendation: The university, hospital (EVO-funding) and state should consider creating 
additional research positions or research rotation schedules to improve the research environment. 
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2.6 Leadership and management in the researcher community 
 Description of  
 the execution and processes of leadership in the RC 
 how the management-related responsibilities and roles are distributed in the RC 
 how the leadership- and management-related processes support 
 high quality research 
 collaboration between principal investigators and other researchers in the RC 
 the RC’s research focus 
 strengthening of the RC’s know-how 
 Identification of the RC’s strengths and challenges related to leadership and management, and the 
actions planned for developing the processes 
ASPECTS: Processes and good practices related to leadership and management 
 
No specific comments in this respect. It seems that the RC is very well led and managed, and the group 
leaders strongly support high quality research. There are collaborations, both clinical ones and those 
based on research work, and there is an excellent working atmosphere for young researchers. 
No specific recommendation on how to further improve this highly satisfactory situation. 
2.7 External competitive funding of the RC 
• The RCs were asked to provide information of such external competitive funding, where: 
• the funding decisions have been made during 1.1.2005– 31.12.2010, and  
• the administrator of the funding is/has been the University of Helsinki 
• On the e-form the RCs were asked to provide: 
1) The relevant funding source(s) from a given list (Academy of Finland/Research Council, 
TEKES/The Finnish Funding Agency for Technology and Innovation , EU, ERC, foundations, other 
national funding organisations, other international funding organizations), and 
2) The total sum of funding which the organisation in question had decided to allocate to the RCs 
members during 1.1.2005– 31.12.2010. 
Competitive funding reported in the text is also to be considered when evaluating this point. 
ASPECTS: Scientific quality, scientific significance, societal impact, innovativeness and future significance 
 
The competitive funding of the RC is very good, and among others the funding by EU and other national 
and international agencies is highlighted. 
The group works in very relevant fields which are important particularly due to the high prevalence of 
the diseases under investigation. 
The group competes well with comparable groups in other European countries and is networking very 
well within Europe. 
2.8 The RC’s strategic action plan for 2011–2013 
• RC’s description of their future perspectives in relation to research and doctoral training. 
ASPECTS: Scientific quality, scientific significance, societal Impact, processes and good practices related to 
leadership and management, national and international collaboration, innovativeness, future significance 
 
Professor Ranki has been among the people in Helsinki who developed strategic planning for the future 
directions of the faculty. Members of the RC have been successful in acquiring external funds in important 
research fields which will direct their future in the next few years. Therefore, the actions for 2011 – 2013 are 
well funded and determined by the recent acquisition of funds. 
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2.9 Evaluation of the category of the RC in the context of entity of 
the evaluation material (1-8) 
The RC’s fitness to the chosen participation category. 
Category 1. The research of the participating community represents the international cutting edge in its field. 
 
The RC fits very well to the chosen participation category. 
Numeric evaluation: 4 (Excellent) 
2.10 Short description of how the RC members contributed the 
compilation of the stage 2 material 
The compilation of the evaluation material has been described by Professor Ranki. No further comments. 
2.11 How the UH’s focus areas are presented in the RC’s research 
Focus area 6: Clinical research 
 
The program fits very well into the UH’s focus areas. 
2.12 RC-specific main recommendations 
The RC has organized itself very well in the past, has sufficient funding for the years to come, is well 
established within the European networks, works on important research fields with high impact in the 
society and recruits excellent young scientists. The recommendation is to consequently follow the path of 
the past years which has proven to be successful. 
2.13 RC-specific conclusions 
The program is involving a highly visible research group within the University of Helsinki with an excellent 
international reputation. This success is based on not only one but several strong researchers who enjoy 
great respect in Europe. 
The RC works on important topics in the field of dermatology and allergy which pertain to large 
segments of the population. 
There is a very positive impression of the work of the group both concerning the past and the future 
perspectives. A stronger support of the group by the university and the hospital should be considered. 
2.14 Preliminary findings in the Panel-specific feedback 
— 
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2.15 Preliminary findings in the University-level evaluation 
Research Focus 
Strengths: High quality scientific research, combination of basic and clinical research. Application into 
common and therefore important skin and allergy diseases. Development of treatments for common 
diseases, and therefore high societal impact and scientific significance. Societal impact is also 
accomplished by visible presence at high level international meetings, in media etc. The research is 
innovative. 
Good networking and scientific cooperation with various research groups outside dermatology and 
allergy. Intensive international cooperation. 
Areas of development correspond to those which can be expected in the future to be important in the 
fields of dermatology and allergy. 
Good level of publications. Of positive note is the involvement of many young talented scientists and 
the promotion of their carriers. 
Recommendations: Recommendation that the group continues their successful work as in the past, 
and the support by the university to the clinical and research efforts is increased. 
 
Practices and Quality of Doctoral Training 
Very good selection and recruitment of doctoral candidates. Stimulation of physician-scientist or MD/PhD 
careers. 
Very good supervision of doctoral candidates, excellent collaboration with other faculties, institutes 
and programs. 
Good practice and quality assessment in doctoral training and assurance of career perspectives by the 
doctoral candidates/fresh doctorates. 
 
Societal Impact 
The RC interacts very well with the society. It is present at many large international meetings, and its work 
is highly visible and well known. An intensive international research network contributes to the visibility of 
research. 
The societal impact is very high due to high quality research in very important skin and allergic 
diseases which are common in the general population. Major contributions have been made in these fields 
by the RC. 
Recommendations: Please consider a higher presence in mass media which are quite interested in the 
fields of skin cancer and allergies. 
 
International and National Collaboration 
Very strong research collaborations and joint activities, among others within EU programs. Very good 
researcher mobility. The recommendation is to continue this successful effort at the same level. 
The group competes well with comparable groups in other European countries and is networking very 
well within Europe. 
 
Leadership and Management 
No specific comments in this respect. It seems that the RC is very well led and managed and the group 
leaders strongly support high quality research. There are collaborations, both clinical ones and those 
based on research work, and there is an excellent working atmosphere for young researchers. 
No specific recommendation on how to further improve this highly satisfactory situation. 
 
External Funding 
The competitive funding of the RC is very good, and among others the funding by EU and other national 
and international agencies is highlighted. 
The group works in very relevant fields which are important particularly due to the high prevalence of 
the diseases under investigation. 
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The group competes well with comparable groups in other European countries and is networking very 
well within Europe. 
 
Strategic Action Plan 
Professor Ranki has been among the experts in Helsinki who developed strategic planning for the future 
directions of the faculty. Members of the RC have been successful in acquiring external funds in important 
research fields which will direct their future in the next few years. Therefore, the actions for 2011 – 2013 are 
well funded and determined by the recent acquisition of funds. 
 
Conclusions and Recommendations 
The program is involving a highly visible research group within the University of Helsinki with an excellent 
international reputation. This success is based on not only one but several strong researchers who enjoy 
great respect in Europe. 
The RC works on important topics in the field of dermatology and allergy which pertain to large 
segments of the population. 
The RC has organized itself very well in the past, has sufficient funding for the years to come, is well 
established within the European networks, works on important research fields with high impact in the 
society and recruits excellent young scientists. The recommendation is consequently to follow the path of 
the past years which has proven to be successful. 
There is a very positive impression of the work of the group both concerning the past and the future 
perspectives. A stronger support of the group by the university and the hospital should be considered. 
The RC has organized itself very well in the past, has sufficient funding for the years to come, is well 
established within the European networks, works on important research fields with high impact in the 
society and recruits excellent young scientists. The recommendation is consequently to follow the path of 
the past years which has proven to be successful. 
 
Summary of the evaluation 
The research, doctoral training, international and national collaboration, leadership and management, 
external funding and strategic action plan received positive comments in the evaluation. The group has 
been successful in the past and offers a good strategic outlook which is supported by recently acquired 
funding. The good perspective is also supported by the recruitment of young talented scientists who will 
carry on the work performed in the past. The group is encouraged to continue their work on the same level 
as previously. 
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3 Appendices 
A. Original evaluation material 
a. Registration material – Stage 1 
b. Answers to evaluation questions – Stage 2 
c. List of publications 
d. List of other scientific activities 
B. Bibliometric analyses 
a. Analysis provided by CWTS/University of Leiden 
b. Analysis provided by Helsinki University Library (66 RCs) 
 
 
 
 
 
International evaluation of research and doctoral training 
at the University of Helsinki 2005-2010 
 
         RC-SPECIFIC MATERIAL FOR THE PEER REVIEW 
 
 
 
 
NAME OF THE RESEARCHER COMMUNITY:  
Department of Skin and allergic diseases (Skin and allergy) 
 
LEADER OF THE RESEARCHER COMMUNITY:  
Professor Annamari Ranki, Departments of Dermatology, Allergology and Venereology, Institute 
of Clinical Medicine 
 
 
RC-SPECIFIC MATERIAL FOR THE PEER REVIEW: 
 Material submitted by the RC at stages 1 and 2 of the evaluation 
- STAGE 1 material: RC’s registration form (incl. list of RC participants in an excel table) 
- STAGE 2 material: RC’s answers to evaluation questions 
 TUHAT compilations of the RC members’ publications 1.1.2005-31.12.2010 
 TUHAT compilations of the RC members’ other scientific activities 1.1.2005-31.12.2010 
 Web of Science(WoS)-based bibliometrics of the RC’s publications data 1.1.2005-31.12.2010 
(analysis carried out by CWTS, Leiden University) 
NB! Since Web of Science(WoS)-based bibliometrics does not provide representative results for most RCs representing 
humanities, social sciences and computer sciences, the publications of these RCs will be analyzed by the UH Library 
(results available by the end of June, 2011) 
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INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
 
Name:  Ranki, Annamari 
E-mail:    
Phone: 47186300 or 0400-875761 
Affiliation:  Department of Skin and allergic diseases 
Street address:  Meilahdentie 2, 00250 Helsinki 
 
 
Name of the participating RC (max. 30 characters): Department of Skin and allergic diseases 
Acronym for the participating RC (max. 10 characters): Skin and allergy 
Description of the operational basis in 2005-2010 (eg. research collaboration, joint doctoral training 
activities) on which the RC was formed (MAX. 2200 characters with spaces):  
The Department of Dermatology and allergology (including also venereology) is among the oldest 
clinical departments of the University Hospital and trains specialists for Skin and allergic diseases. 
The multidisciplinary composition of the Department is unique at the European level.  The unit's 
research focuses on the following interconnected main areas: skin cancer, inflammation and 
immunity . Also, studies on the genetics of multifactorial disease, especially  psoriasis, lupus 
erythematosus  and autoinflammatory diseases, in collaboration with international genetics 
groups and centers of excellence are an important part of the research. The departments’  PhD 
students are often funded through the National Clinical Graduate School, and the major research 
groups have external funding from e.g. the Academy of Finland, Tekes and  EU FP7.  International 
collaboration is very active, foreign scientists and exchange students pay annual visits and our own 
scientists and PhD students visit foreign collaborating labs regularly.  
 
 
Main scientific field of the RC’s research: Dermatology 
RC's scientific subfield 1: Allergology 
RC's scientific subfield 2: Oncology  
RC's scientific subfield 3:  
RC's scientific subfield 4:  
Other, if not in the list: Autoinflammatory and autoimmune skin diseases, borreliosis, venereal diseases 
 
Participation category: 1  
Justification for the selected participation category (MAX. 2200 characters with spaces):  1 (justification 
was given on the webpage already) 
1 RESPONSIBLE PERSON 
2 DESCRIPTION OF THE PARTICIPATING RESEARCHER COMMUNITY (RC) 
3 SCIENTIFIC FIELDS OF THE RC 
4 RC'S PARTICIPATION CATEGORY 
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INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
 
 
Public description of the RC's research and doctoral training (MAX. 2200 characters with spaces):  
The research performed at the Department of Skin and allergic diseases reflects a combination of clinical 
(atopic eczema, CTCL and HIV DNA vaccine studies) and experimental (molecular background of melanoma 
and non-melanoma skin cancer and skin lymphomas,  mechanism of contact allergy, mouse models for 
psoriasis and contact dermatitis) activities. The department is currently participating in three EU-supported 
research projects or networks: the MAARS, the EPIDERM and the SYSGEMET.  Also, the department is a 
member of the EORCT Cutaneous Lymphoma task Force. The research is mostly translational, based on 
clinically relevant problem-solving and applying the demands of personalized medicine.  Our department 
has had a pioneering and active role in establishing the National Clinical Graduate School. The research-
supporting atmosphere of the departments apparently has allured young scientists, since  more than half of 
those applying for a resident post have already achieved their PhD in some theoretical field.   
Significance of the RC's research and doctoral training for the University of Helsinki (MAX. 2200 
characters with spaces):  
Many of our senior scientists act as Board members and opinion-leaders in both scientific and professional 
societies of our disciplines in Finland, in Europe and worldwide. Through this activity, both science policy 
and health care decision-makers are informed and influenced, like through the European Dermatology 
Forum (Prof. Ranki as Secretary-General in 2007-2009 and as President in 2010). Prof. Karvonen acted  as 
the Chief Executive Physician for Helsinki and Uusimaa health care district and is actively involved in science 
policy, too.  At the European level, our hospital is one of the centres of excellence in the Global Allergy 
European Network (Galen). We have produced a considerable number of PhD theses, several approved 
with distinction.  
In implementing research IPR  we have been very active, several patent applications have been filed (two 
patents granted) and we have produced new diagnostic t tools, currently being commercialized by Finnish 
companies. Also, based on our initial scientific work, clinical trials with a Finnish HIV DNA vaccine trials are 
ongoing.  We are also actively collaborating with several  patient associations and small companies, our 
potential clients . This has lead to improved awareness of the burden of skin diseases and skin cancer.  
Keywords: dermatology, contact allergy, atopy, skin cancer, lymphoma, psoriasis, TRAPS, borrelia 
 
 
Justified estimate of the quality of the RC's research and doctoral training at national and international 
level during 2005-2010 (MAX. 2200 characters with spaces):  
We assume the evaluators will respond to this question. All our active senior scientists have a Hirsch index 
between 31 – 41, perhaps this tells you something.  
 
Comments on how the RC's scientific productivity and doctoral training should be evaluated (MAX. 2200 
characters with spaces): Normal evaluation criteria can be applied.  
5 DESCRIPTION OF THE RC'S RESEARCH AND DOCTORAL TRAINING 
6 QUALITY OF RC'S RESEARCH AND DOCTORAL TRAINING 
LIST OF RC MEMBERS
NAME OF THE RESEARCHER COMMUNITY: Skin and allergy
RC-LEADER A. Ranki
CATEGORY 1
Last name First name
PI-status 
(TUHAT, 
29.11.2010)
Title of research and 
teaching personnel Affiliation 
1 Ranki Annamari x IV Professor Dept. of Dermatology
2 Saksela Olli x IV Professor Dept. of Dermatology
3 Reitamo Sakari x IV Professor Dept. of Dermatology
4 Lauerma Antti x IV Professor Dept. of Dermatology
5 Remitz Anita x III Senior Researcher Dept. of Dermatology
6 Heikkilä Hannele x III Senior Researcher Dept. of Dermatology
7 Panelius Jaana x III Senior Researcher Dept. of Dermatology
8 Ackermann Leena x III Senior Researcher Dept. of Dermatology
9 Väkevä Liisa II Postdoctoral Researcher Dept. of Dermatology
10 Hahtola Sonja II Postdoctoral Researcher Dept. of Dermatology
11 Suomela Sari II Postdoctoral Researcher Dept. of Dermatology
12 Koskenmies Sari x II Postdoctoral Researcher Dept. of Dermatology
13 Virtanen Hannele II Postdoctoral Researcher Dept. of Dermatology
14 Pesonen Maria II Postdoctoral Researcher Dept. of Dermatology
15 Hannula-Jouppi Katariina II Postdoctoral Researcher Dept. of Dermatology
16 Bouchard Laura II Postdoctoral Researcher Dept. of Dermatology
17 Timonen Kaisa II Postdoctoral Researcher
18 Mälkönen Tarja x II Postdoctoral Researcher Dept. of Dermatology
19 Kuivanen Tiina II Postdoctoral Researcher Dept. of Dermatology
20 Hiltunen-Back Eija x II Postdoctoral Researcher Dept. of Dermatology
21 Kainu Kati II Postdoctoral Researcher
22 Jeskanen Leila Dept. of Dermatology
23 Karvonen Seija-Liisa IV Professor (deceased) Dept. of Dermatology
24 Saarialho-Kere Ulpu III Senior Researcher (deceased) Dept. of Dermatology
25 Maliniemi Pilvi I Doctoral candidate Dept. of Dermatology
26 Carlsson Emilia I Doctoral candidate Dept. of Dermatology
27 Niiranen Kirsi III Senior Researcher Dept. of Dermatology
28 Siitonen Annika II Postdoctoral Researcher
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Name of the RC’s responsible person: Ranki, Annamari 
E-mail of the RC’s responsible person:   
Name and acronym of the participating RC: ): Department of Skin and allergic diseases, Skin and allergy 
The RC’s research represents the following key focus area of UH: 6. Kliininen tutkimus – Clinical research 
Comments for selecting/not selecting the key focus area: The Department of Dermatology and allergology 
(including also venereology) is among the oldest clinical departments of the University Hospital and trains 
specialists for Skin and allergic diseases. The multidisciplinary composition of the Department is unique at 
the European level.  Translational research, starting from research targets identified bedside, brought to 
the laboratory and back to the clinic for diagnostics or therapy are central in our research. Currently, the 
research focuses on the following interconnected main areas: skin cancer, inflammation and immunity . 
Also, studies on the genetics and pathomechanism of multifactorial disease, especially  psoriasis, lupus 
erythematosus  and autoinflammatory diseases, in collaboration with international genetics groups and 
centers of excellence are an important part of the research. 
 
 
 Description of the RC’s research focus, the quality of the RC’s research (incl. key research 
questions and results) and the scientific significance of the RC’s research for the research 
field(s).  
The unit's dermatologic research focuses on two main areas: skin cancer (incl. cutaneous lymphomas) 
and immune-mediated skin diseases. Studies on the genetics of multifactorial disease, especially  
psoriasis, asthma, lupus erythematosus  and autoinflammatory syndromes are conducted in 
collaboration with international genetics groups whiuch has resulted in several original discoveries.  
 
Within skin cancer, the aim of Prof. Ranki’s group is to provide new means for the diagnosis, 
classification and, ultimately, targeted therapy of cutaneous T-cell lymphomas (CTCL) and recently, aslos 
for some other common cancers. The first CTCL-associated gene translocation/deletion has bveen 
identified, patented and is being developed for a new molecular biologic diagnostic test and biomarker. 
The group has also shown that this new cancer-associated gene is aberrated and correlates with 
patients survival in colorectal cancer and brain tumors. Also, the group has made novel findings on 
inflammation and cancer in a subtype of CTCL and functional studies on the gene aberrations identified 
are being carried out.  
 
Mechanisms in epithelial carcinogenesis and invasion (basal and squamous cell cancers) constituted the 
main objectives of the late Prof. Saarialho-Kere’s group. The role of proteases and inflammation, in 
particular, in the processes of epithelial cell migration during normal and aberrant cutaneous and 
intestinal wound repair (chronic wounds, inflammatory bowel disease), tissue destruction and 
inflammation were studied  both on cell and tissue levels utilizing epithelial cell cultures and 
overexpressing cell lines, regulation studies, patient tissue samples, and certain mouse and array 
models.  
 
BACKGROUND INFORMATION 
1 FOCUS AND QUALITY OF RC'S RESEARCH (MAX. 8800 CHARACTERS WITH SPACES) 
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The unit’s melanoma research focuses, firstly, on identifying genes and proteins responsible for human 
melanoma progression using genome-wide microarray expression and proteome analyses. Doc. 
Saksela’s group has identified several gene expression changes potentially involved in  invasiveness and 
metastasis. The goal is to use the expression profiling data in the development of assays for detecting 
clinically occult melanoma micrometastases in sentinel lymph nodes.  Samples have been collected from 
over 500 melanoma patients. Secondly, the regulation of melanocyte proliferation and apoptosis in 
response to different growth factors are targeted. The factors influencing survival of melanocytes have 
been studied in a novel  model of a three-dimensional collagen gel developed by Dr. vonWillebrand. 
 
Psoriasis is one of the major chronic skin diseases, and our psoriasis  research focuses, firstly, on  tumor 
suppressor protein NF1 (neurofibromin) and its function in psoriatic epidermis and in keratinocyte 
cultures (late Dr. S-L. Karvonen). Clinical trials with new, biologic treatments for psoriasis are ongoing, 
too.  
 
In collaboration with geneticists, the susceptibility genes for psoriasis and lupus erythematosus, and  
TNF-receptor SF1A mutations underlying the periodic fever syndromes like TRAPS have been studied. 
Original findings, such as  the discovery of the HCR gene and TNFRSF1A mutations causing TRAPS have 
been made, and functional characterization of the corresponding altered proteins were recently 
described. Furthermore, both genotype-phenotype correlation and linkage studies involving other 
psoriasis susceptibility loci are ongoing as well as cloning of susceptibility genes in HCR-negative 
patients.  
 
Both basic and clinical studies on atopy form one major research area. Prof.Lauerma's group focuses in  
skin immunology, allergology, and microbiology, and the combination of these three. The group's 
research quality is high and the group has good, direct approaches in research questions in our field that 
have a major impact on the research problems in our fields. 
 
Clinical studies on atopy, performed by Dr. Reitamo’s group, target the is introduction of new 
immunomodulatory therapies  with improved risk/benefit ratio compared to corticosteroid-based 
treatment. The ongoing research includes topical immuno-modulatory treatment for childhood atopic 
dermatitis, mechanism of intermittent preventive treatment and studies on the  adverse events 
associated with topical immunomodulatory treatment. 
 
The strong clinical immunologic knowledge within the department has resulted also in the active  
participation in DNA vaccine trials for HIV infection (Prof. Ranki), and all information thus obtained  will 
now be exploited in tumour vaccine development for CTCL (MIMOVAC EU-LOI approved).    
 
The Department's research has resulted in broad international networking and co-operation (e.g. 
participation in two EU-funded projects and networks, EORTC Cutaneous lymphoma Task Fore, ISCL 
Board). The senior group leaders of the Skin and allergy RC are appreciated international opinion-
leaders, based both on their research and clinical knowledge. 
 
 Ways to strengthen the focus and improve the quality of the RC’s research. 
Identification of key target areas, in relation to competitiveness in the international field, joining as well 
methodological skills as intellectual knowledge and creativity. Joint major grant applications are a target 
in the future. Quality of the research can be improved only if more research-priviledged time can be 
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guaranteed to our medical PhD strudents and especially to the clinical seniors supoervising the work. 
This has bnot been the case durting thr past, since the community finances (hispital budget) has dictated 
the work load. The University Hospital does not enough respect clinical research although the Academy 
of Finland has woken up on this matter lately.  
 
International reserarch exchange is also important and we do have good experience already. 
 
 
  How is doctoral training organised in the RC? Description of the RC’s principles for recruitment and 
selection of doctoral candidates, supervision of doctoral candidates, collaboration with faculties, 
departments/institutes, and potential graduate schools/doctoral programmes, good practises and 
quality assurance in doctoral training, and assuring good career perspectives for the doctoral 
candidates/fresh doctorates.  
Currently about 50% of those applying for a resident position in Skin and allergic diseases has already a 
PhD degree. We have 9 resient positionv in the clinic and currently ca. 18 residents candidates in the 
line. Thus, research is encouraged for those waiting for their permannen residency. Prof. Ranki was the 
primus motor and chairperson for worjing group to create the  National Clinical Graduate School - now 
supported by the Academy of Finland. Thus, a proportion of the PhD srtudents are enrolled in this or the 
HBGS graduate schools.  During the past years, also M.Sci-based  Ph.D. students have been recruited 
through formal recruitment and interview processes.  However, when  possible, M.D./Ph.D. students are 
recruited like Ph.D. students, but due to their scarcity as full-time scientists, this is a goal that needs to 
be solved during next period. 
 
Doctoral candidates are supervised by post-docs in the group and through group meetings, as well as 
weekly seminars. All PhD students regularly present their data at the National Skin Reseach event, and 
in international meetings.  
 
Assuring good career for the PhDs is almost impossible within the hospital setting but the Medical 
faculty/University has now initiated a tenure track system which will help the medical PhDs. One main 
problem si that the University has absolutely no other funds than the salaries for the permanent staff !  
Even staff has to take leave of absence without pay for the summer months. Thus, very difficult to cope 
with e.g. well-funded international groups and the rising ones from China/India in the futire. 
 
 RC’s strengths and challenges related to the practises and quality of doctoral training, and the actions 
planned for their development. 
Chronic lack of money from the University and the steadily decreasing State subsidy (EVO) for research 
is a major limitation for recruiting especially post-doctoral scientists, returning from excellent labs 
abroad. Also, difficulty in obtaining research months after the PhD and to hire skilful lab technicians for 
longer periods. Postdocs are in demand  as cores of research groups.  
 
The Department  has modern laboratory space at the clinic itself, next to the dermatopathology lab, and 
also in Biomedicum Helsinki.  This intimate relationship provides advantages to the research being 
performed in the form of effectiveness and easy access to expert opinion.  
 
2 PRACTISES AND QUALITY OF DOCTORAL TRAINING (MAX. 8800 CHARACTERS WITH SPACES) 
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Coordination between research groups to increase efficiency in reseach is necessary, and there seems to 
be still too little cross talk and collaboration between the two disciplines (Dermatovenereology-
/Allergology) in ideas, utilizing machines and patient materials. Also, more interaction with FIMM needs 
to be initiated, along the Translational research center (originally suggested to HUCH by Prof. Ranki) 
 
 
 
 
 
 
 
 Description of how the RC interacts with and contributes to the society (collaboration with public, 
private and/or 3rd sector).  
The popularisation of science and medicine during the last two decades through media  has lead to a 
confrontation between scientists and an informed and critical public.  With people getting better 
education, they have to be made aware not only about benefits but also about the risks and problems in 
modern research. Scientific facts are often replaced by a network of contradictory findings especially in 
the internet.  
 
We have made a serious attempt to leave ivory tower by publicizing our research projects, giving more 
lectures both to all levels of health care professionals and general public through patient organizations.  
Our professors also act as Section Editors/ Editorial Boprd members for several Journals of our field.  As 
a general trend in most Western countries, society and politicians have pushed  the University for not 
only academic research but also for business orientation.  Professor Ranki’s group has been developing a 
HIV vaccine by active collaboration with a Finnish non-governmental biotechnology company . 
Both the patient associations and small companies can be seen as our potential clients whom we have 
invited  to collaborate in the development of research projects. This has lead to improved awareness of 
the mutual benefits of collaboration 
 
Skin diseases, such  as allergy, will be the burden of more than 50% people in generation now in their 
twenties (born during 1980's), according to research done in Helsinki Metropolitan Area (See Pallasaho 
et al., 2008). Skin cancer problems will double or triple during next 20 years, as  life-expentancy raises 
about two-, or three-fold in population over the age 70 (See Tilastokeskus publication, 2010). Thus, 
novel interventions need to be established. The Skin and allergy RC has regularly filed patents and some 
granted patents are being further developed by commercial companies at the moment. 
 
 Ways to strengthen the societal impact of the RC’s research and doctoral training. 
 
The RC is performing mostly translational research which implies everyday contact to the public 
(university) hospital sector and also, to the Pharma.  Prof. Ranki is member of the University Hospital 
University Committee, the Board for Medical care and also deputy member of FIMM Board and through 
these activities the societal impact of the RC’s research will be communicated.  As the President of the 
EDF, prof. Ranki arranged a meeting with the EU Commissioner of Health, Mr. John Dalli in June 2010,  
and activities with his office will continue in the coming years as agreed and through the EDF.  The RC 
senior members will be active in delivering lectures on our research topics (like skin cancer and 
3 SOCIETAL IMPACT OF RESEARCH AND DOCTORAL TRAINING (MAX. 4400 CHARACTERS WITH SPACES) 
  
5 
 
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 2 MATERIAL  
 
 
allergology) for the general public (Studia Generalia, EPIDERM project) and all PhD srtudents will be 
involved in such activities, too. The students will participate in the national Student Fair , too. We shall 
keep active our contact with the various patient organizations (psoriasis, atopy, allergology, APECED 
etc.). Recently, some new research activities have been initiated together with a patient organization 
and some PhD students are involved in this activity, too.   
SME companies will be considered as important partners (as is the case for our ongoing EU grants and 
applications)  and our PhD students will thus get insight into future career possibilities.  
At the international level, we shall expand  e.g. Erasmus, Marie Curie and CIMO student exchange.   
 
 
 
 
 
 
 Description of the RC’s research collaborations and joint doctoral training activities and how the RC 
has promoted researcher mobility.  
 
Reseach collaborations:  
The group of late Prof. Saarialho-Kere collaborates with the following groups: Dr. Marikki Laiho, Prof. 
Veli-Matti Kähäri, Univ. of Turku; Dr. O. Rollman; Dr. Jyrki Vuola and Dr. Virve Koljonen, Dept. of Plastic 
Surgery, Helsinki University Hospital, Helsinki;  Prof. Juha Kere, Karolinska Institute, Novum, Huddinge; 
and Department of Medical Genetics, UH; Outi Elomaa, PhD, and group at the Department of Medical 
Genetics, UH; Esko Kankuri, MD, PhD, Institute of Biomedicine, Pharmacology, UH; Tuula Nyman, PhD, 
Institute of Biotechnology, Protein Chemistry Laboratory, UH; Raija Sormunen, PhD, Core Facility of 
Electron Microscopy, University of Oulu.  
 
Also, Dr. Hannula-Jouppi's research is carried out in collaboration with Prof. Juha Kere's group. One 
doctoral thesis has been finished in the LERU -program between these two universities (Sara Bruce 
2009) and a second doctoral thesis is underway (Mari Muurinen).  
 
Research on atopic diseases:  
The thesis project of Dr. Maria Pesonen was performed as a joint project of the Department of 
Dermatology and Allergology, and the Department of Pediatrics, University of Helsinki. THrough the 
work of mainly acting Prof. Reitamo and Prof. Lauerma, the RC is one of 10 leading groups in skin 
allergology and immunolgy in its own fields. 
 
Melanoma field researchers collaborate with groups at the Dept. of Biomedicine, UH (Doc. Hölttä), Dept. 
of Plastic Surgery (Doc. Jahkola, Tiina); Poland (Podlasz, Piotr); and the pathologists from Helsinki and 
Tampere University Hospitals.  
 
Prof. Ranki's group currently collaborates with Doc. Sampsa Hautaniemi, DTech, Computational Systems 
Biology Lab., Institute of Biomedicine, UH; Doc. Hannu Haapasalo and Prof.emer. Kai Krohn, Tampere 
University Hospital; Prof. Martti Färkkilä, Dept. of Gastroenterology, HUCH;  Prof. Christine Leib-Moesch, 
Inst. of Virology, GRCEH, Neuherberg, Germany and Ass. prof. Christoph Klein, Div. of Oncogenomics, 
Univ. Regensburg, Regensburg, Germany, and Professor Rudolf Stadler, Comprehensive Cancer Center, 
4 INTERNATIONAL AND NATIONAL (INCL. INTERSECTORAL) RESEARCH COLLABORATION AND RESEARCHER 
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University of Hannover, Medical Centre Minden, Germany and with the whole of the EORTC Cutaneous 
LYmphoma Task Force . 
 
 RC’s strengths and challenges related to research collaboration and researcher mobility, and the 
actions planned for their development. 
The RC's international research collaboration is active and fruitful: EU-funded EUROTransBio, EPIDERM 
and MAARS projects, and the MIMOVAC project which has passed 1st step. EORTC clinical trials 
participation. We have annually 2-4 international medical students working in the lab fro short periods 
and currently one Erasmus student. We will exploit European and also other international mobility 
programmes and our wide personal contacts worldwide.  
As an example of the international networking, Prof. Ranki was recently awarded the International 
League of Dermatological Societies’n (ILDS) Award Certificate of appreciation. 
 
 
 
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties).  
 
The RC has a  shared research lab together with the Department of Oncology in the Biomedicum 
Helsinki. This has eased  cell culture, molecular biology, and transfection and more  sophisticated new 
research activities.  As permanent research resources, we have 1,5 technicians from HUCH and two 
modern and fully equipped research laboratories (with e.g. Metasystems Metafer-working station, 
LightCycler® 480, sorting FACS), one in Biomedicum Helsinki and the other in the Skin and allergy 
hospital, in close proximity to the operation rooms. The animal facilities we use are in Biomedicum 
Helsinki. Continuing discussions and collaborations with labs representing other relevant disciplines at 
Biomedicum and possibility to easily attend high-class basic research seminars is very valuable. PhD 
students at our department are strongly encouraged to interact and collaborate with other research 
groups in the Biomedicum and to seek international contacts by presenting their data in European and 
American meetings.  However, limited space, especially office tables for individual PhD students and 
group leaders, is still a problem 
 
Important interests of the group are also clinical investigator-initiated research projects at the moment 
(e.g. the MAARS project to start in 2011). The laboratory,  deep-sequencing, and bioinformatics 
strengths are in collaborations  within Finnish Institute of Occupational Health, Karolinska   
 
Institutet, King's College London, Heinrich Heine University of  Duesseldorf, INSERM Paris, as well as a 
bioinformatics start-up  company in Edinburgh. 
 
Balance between research and teaching duties is not a major problem, but rather balance between the 
heavy clinical burden and research. We do not have privileged time for research. The first step would be 
to generate enough part-time research positions (like in e.g. Karolinska Sjukhuset)  to the HUCH. This 
has been discussed for at least a decade but only a few such competitive positions are currently 
available- 
 
5 OPERATIONAL CONDITIONS (MAX. 4400 CHARACTERS WITH SPACES) 
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 RC’s strengths and challenges related to operational conditions, and the actions planned for their 
development. 
 
A major challenge is how to cope with the strong mismatch between research expectation & support 
within the HUCH and with the almost non-existing resources from the  faculty and for staff 
development. The cost of investigator-initiated clinical research is very high due to several factors such 
as the hospital charges for study patients. This makes future academy-initiated clinical trials almost 
impossible.  Also, the operational structure/bureaucracy within the organisation has become very 
complicated without corresponding benefits for the research.  These problems must be targeted jointly, 
one RC alone cannot do much.  
 
We have main strengths to  obtain our goals in Europe. However, competition with NIH-funded  
research coalitions in the U.S.A. face us a problem, if we want to be  the first in our fields globally. 
 
We will continue to recruit enough research-active postdocs  although their later positions in the HUCH 
setting is difficult to guarantee. Also, our main target is to harmonize the somewhat diverse spectrum of 
interests of the principal investigators within our RC and we have already made progress in this aspect.  
Although the growing Meilahti campus, Biomedicum and the large Helsinki University network  provides 
proactive partnerships for research projects, we must be active in being part of the translational 
research network within the campus. We have already started our own Skin Research  and 
genodermatosis sample biobanking (at the FIMM facilities). Also, in 2011 we finally got the long-sought 
skin cancer and cutaneous lymphoma registries, which will include biomarker data as well. These 
registries are unique and most complete (virtual) at the international level and e.g. the ISCL will modify 
its own registry accordingly.  
 
 
 
 Description of the execution and processes of leadership in the RC, how the management-related 
responsibilities and roles are distributed in the RC and how the leadership- and management-related 
processes support high quality research, collaboration between principal investigators and other 
researchers in the RC, the RC’s research focus and strengthening of the RC’s know-how.  
 
The individual research groups within the RC are independent but also, our research is highly 
networked.  Our projects are in forefront of today's dermatological science. As today funding from 
outside sources is critical, our base is strong both from Academy of Finland and European Commission. 
Thus, the management responsibilities are within each group itself and according to the structure 
described in each Academy/ EU project. Professor Ranki as department chair favours individual 
responsibility and her task is to coordinate the joint goals in e.g. infrastructure funding, recruitment and 
outside communication for the department. Both Prof. Ranki and Prof. Lauerma have degrees in 
Administration.      
The RC is relative small so that everyday communication between PIs is a reality and poses no problems. 
We have altogether 14  Ph.D. students, top collaborators, funding from, e.g., Academy of Finland and 
European Commission, and clear vision of future research in the EU-funded project MAARS. 
 
 
6 LEADERSHIP AND MANAGEMENT IN THE RESEARCHER COMMUNITY (MAX. 4400 CHARACTERS WITH SPACES) 
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 RC’s strengths and challenges related to leadership and management, and the actions planned for 
developing the processes. 
 
Since the RC is relative small so that everyday communication between PIs is a reality and poses no 
problems. We will, however, organize regular bi-monthly meeting for the whole RC in the future to 
facilitate interaction and coordination.  
 
 
 
 Listing of the RCs external competitive funding, where: 
- the funding decisions have been made during 1.1.2005-31.12.2010, and 
- the administrator of the funding is/has been the University of Helsinki 
 
 Academy of Finland (AF) - total amount of funding (in euros) AF has decided to allocate to the RC 
members during 1.1.2005-31.12.2010: Ranki A 2005-2006  100000, late U Saarialho-Kere 180000, S 
Suomela 41000 
 
 Finnish Funding Agency for Technology and Innovation (TEKES) - total amount of funding (in euros) 
TEKES has decided to allocate to the RC members during 1.1.2005-31.12.2010: Ranki A 2003-2005  
122752 e 
 
 European Union (EU) - total amount of funding (in euros) EU has decided to allocate to the RC members 
during 1.1.2005-31.12.2010: Ranki EuroTransBio 2007  49900, Ranki EPIDERM (HUCH), Lauerma/Ranki  
MAARS 6m€ 
 
 European Research Council (ERC) - total amount of funding (in euros) ERC has decided to allocate to the 
RC members during 1.1.2005-31.12.2010:  
 
 International and national foundations – names of international and national foundations which have 
decided to allocate funding to the RC members during 1.1.2005-31.12.2010, and the amount of their 
funding (in euros).  
- names of the foundations: Sigrid Juselius Foundation; Finnish cancer Association, Finska 
Läkaresällskapet 
- total amount of funding (in euros) from the above-mentioned foundations: Ranki 390000; 
Saarialho-Kere 121000; Saksela 340000, Panelius 60000 
 
 Other international funding - names of other international funding organizations which have decided to 
allocate funding to the RC members during 1.1.2005-31.12.2010, and the amount of their funding (in 
euros). 
- names of the funding organizations: Vetenskapsrådet, Sweden; AF 
- total amount of funding (in euros) from the above-mentioned funding organizations: will be 
completed later 
 
7 EXTERNAL COMPETITIVE FUNDING OF THE RC 
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 Other national funding (incl. EVO funding and Ministry of Education and Culture funded doctoral 
programme positions) - names of other national funding organizations which have decided to allocate 
funding to the RC members during 1.1.2005-31.12.2010, and the amount of their funding (in euros). 
- names of the funding organizations: Helsinki University Hospital Research Funds 
- total amount of funding (in euros) from the above-mentioned funding organizations: Ranki 230000, 
Saarialho-Kere 130000, Saksela 130000, Suomela 70000 
 
 
 
 Description of the RC’s future perspectives in respect to research and doctoral training. 
Prof. Ranki has actively participatred in the Faculty's plans to improve various aspects of the doctoral 
training when acting as Vice Dean. An important target  will be to facilitate methodological knowledge 
through active international exchange, as has already been done.  Short visits by collaborating 
professors are palnned through various funding possibilities. The EU-funded MAARS (Microbes in Allergy  
and Autoimmunity Related to Skin) project will be one central activity during the future years. Antti 
Lauerma is  Vice-Coordinator of the project and Annamari Ranki the PI for UH. The project is in final 
signature phase in  European Commission, and will include 6.000.000 euros funding over  2011-2015 for 
the project, distributed among 10 Partnes. Also, a recent external funding for Prof. Ranki and 
collaborating international research groups on Infammation and autoimmunity will be among the 
sentral topics. UH Research department, however, declined this funding which has now been redirected 
through the CRI-HUCH. 
 
 
 
 
Sorry to say but this time the evaluation process information has NOT reached the research community 
very well. The RC members have not quite internalized the effort although Prof. Ranki as Dept. Chair has 
forwarded all available information. E-mails from unknown persons in University Administration are not 
very encouraging. Even I myself, although centrally participating in the first UH research evaluation, 
have had great dificulties in grasping what to do and when. No help or time for this work has been 
allocated. THus, the RC has ratrher concentrated on ongoing research anc clinical activities in the clinic. 
It's had to perform this task on top of a 12-hour day ! 
8 RC’S STRATEGIC ACTION PLAN FOR 2011–2013 (MAX. 4400 CHARACTERS WITH SPACES) 
9 SHORT DESCRIPTION OF HOW THE RC MEMBERS HAVE CONTRIBUTED TO THE COMPILATION OF THE STAGE 2 
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1 Analysis of publications 
 
- Associated person is one of Annamari Ranki ,  Sakari Reitamo ,  Antti Lauerma ,  
Anita Marianne Remitz-Reitamo ,  Hannele Heikkilä ,  Jaana Panelius ,  Leena 
Ackermann ,  Liisa Väkevä ,  Sonja Hahtola ,  Sari Suomela ,  
Sari Koskenmies ,  Hannele Virtanen ,  Maria Pesonen ,  Katariina Sara Eriikka Hannula-
Jouppi ,  ,  Laura Bouchard ,  Tarja Mälkönen, Tiina Kuivanen , 
 Eija Hiltunen-Back ,  Kati Hannele Kainu ,  Leila Jeskanen ,  Seija-
Liisa Karvonen, Ulpu Saarialho-Kere, Kirsi Niiranen ,  Annika Siitonen ,  
 
Publication year 
Publication type 2005 2006 2007 2008 2009 2010 
Total Count 2005 - 
2010 
A1 Refereed journal article 19 18 23 19 19 25 123 
A2 Review in scientific journal   1 1   2 
A3 Contribution to book/other compilations (refereed) 1 1  1   3 
A4 Article in conference publication (refereed)      1 1 
B1 Unrefereed journal article 2 8 4 4 2 4 24 
C2 Edited book, compilation, conference proceeding or special issue of 
journal 
   1   1 
D1 Article in professional journal      1 1 
D2 Article in professional hand or guide book or in a professional data 
system, or text book material 
    1  1 
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2 Listing of publications 
A1 Refereed journal article 
2005 
Aaltonen, L, Cajanus, S, Bäck, L, Nieminen, P, Paavonen, J, Ranki, A 2005, 'Extralaryngeal HPV infections in male patients with adult-
onset laryngeal papillomatosis', European Archives of Oto-Rhino-Laryngology, vol 262, no. 9, pp. 708-712. 
Abecasis, G, Allen, M, Barker, J, Kere, J, Burden, D, Capon, F, Christophers, E, Elder, JT, Gudjonsson, JE, Huffmeier, U, Jenisch, S, 
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